A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab.
Phase of Trial: Phase III
Latest Information Update: 27 Jan 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 27 Jan 2018 Results assessing the safety of Adalimumab Dosed Every Week and Every Other Week in patients from this and 12 other studies, published in the American Journal of Clinical Dermatology
- 15 Jun 2013 Planned number of patients changed from 1469 to 1500 as reported by European Clinical Trials Database.
- 18 Nov 2010 Additional locations added as reported by ClinicalTrials.gov.